Sökning: onr:"swepub:oai:DiVA.org:su-203110" >
Gut Dysbiosis and F...
Gut Dysbiosis and Fecal Calprotectin Predict Response to Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma
-
Ponziani, Francesca Romana (författare)
-
De Luca, Angela (författare)
-
- Picca, Anna (författare)
- Stockholms universitet,Centrum för forskning om äldre och åldrande (ARC), (tills m KI),Policlinico Universitario Agostino Gemelli IRCCS, Italy
-
visa fler...
-
Marzetti, Emanuele (författare)
-
Petito, Valentina (författare)
-
Del Chierico, Federica (författare)
-
Reddel, Sofia (författare)
-
Paroni Sterbini, Francesco (författare)
-
Sanguinetti, Maurizio (författare)
-
Putignani, Lorenza (författare)
-
Gasbarrini, Antonio (författare)
-
Pompili, Maurizio (författare)
-
visa färre...
-
(creator_code:org_t)
- 2022-03-09
- 2022
- Engelska.
-
Ingår i: Hepatology Communications. - : Ovid Technologies (Wolters Kluwer Health). - 2471-254X. ; 6:6, s. 1492-1501
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- The gut microbiota is a well-known prognostic factor and a modulator of treatment sensitivity in patients with cancers treated with immune checkpoint inhibitors. However, data on hepatocellular carcinoma (HCC) are lacking. This study aimed to evaluate the prognostic role of the gut microbiota and changes produced by immunotherapy on the intestinal environment in patients with cirrhosis and HCC. Eleven patients treated with Tremelimumab and/or Durvalumab were included in the analysis. All study participants underwent gut microbiota profiling, quantification of fecal calprotectin, serum levels of zonulin-1, lipopolysaccharide binding protein (LBP), and programmed death-ligand 1 (PD-L1) at baseline and at each treatment cycle until the third cycle, then every three cycles until treatment discontinuation or last visit. The 6 patients who achieved disease control (DC) showed lower pretreatment fecal calprotectin (median, 12.5; interquartile range [IQR], 5-29 vs. median, 116; IQR, 59-129 µg/g; P = 0.047) and PD-L1 serum levels (median, 0.08; IQR, 0.07-0.09 vs. median, 1.04; IQR, 0.17-1.95 ng/mL; P = 0.02) than nonresponders. The relative abundance of Akkermansia (log2 fold change [FC], 2.72; adjusted P [Padj] = 0.012) was increased, whereas that of Enterobacteriaceae (log2 FC, −2.34; Padj = 0.04) was reduced in the DC group. During treatment, fecal calprotectin showed a temporal evolution opposite to the Akkermansia to Enterobacteriaceae ratio and gut microbiota alpha diversity, but similar to zonulin-1 and LBP. Bifidobacterium had a stable behavior in patients with a long follow-up, while Akkermansia was more variable. Akkermansia and Bifidobacterium showed similar temporal patterns and causative relationships with Prevotella, Veillonella, Ruminococcus, Roseburia, Lachnospira, Faecalibacterium, and Clostridium. Conclusion: A favorable composition of the gut microbiota and low intestinal inflammation are associated with achieving DC. The intestinal environment changes dynamically during therapy.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Gastroenterologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Ponziani, France ...
-
De Luca, Angela
-
Picca, Anna
-
Marzetti, Emanue ...
-
Petito, Valentin ...
-
Del Chierico, Fe ...
-
visa fler...
-
Reddel, Sofia
-
Paroni Sterbini, ...
-
Sanguinetti, Mau ...
-
Putignani, Loren ...
-
Gasbarrini, Anto ...
-
Pompili, Maurizi ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Gastroenterologi
- Artiklar i publikationen
-
Hepatology Commu ...
- Av lärosätet
-
Stockholms universitet
-
Karolinska Institutet